Table 1.
Baseline characteristics among subjects with CAD groups
| Stable CAD (n=1499) | Unstable Angina (n=346) | Non-ST elevation Myocardial Infarction (n=160) | ST-elevation Myocardial Infarction (n=23) | P-Value* | |
|---|---|---|---|---|---|
| Age, years mean (SD) | 65.2 (11.6) | 65.5 (12) | 66.7 (11.6) | 60.8 (11.4) | 0.09 |
| Male n (%) | 1040 (69.38) | 203 (58.67) | 97 (60.63) | 17 (73.91) | <0.001 |
| Black n (%) | 353 (23.55) | 62 (17.92) | 51 (31.88) | 8 (34.78) | 0.003 |
| Body Mass Index kg/m2 mean (SD) | 29.3 (6) | 29.9 (6) | 29.6 (6.4) | 29.6 (3.9) | 0.23 |
| Estimated GFR mL/min/1.73 m2 mean (SD) | 71.1 (24.8) | 72.3 (23.8) | 68.2 (25) | 80.5 (19.9) | 0.18 |
| Smoking n (%) | 962 (64.26) | 237 (68.5) | 106 (66.25) | 12 (52.17) | 0.26 |
| Diabetes n (%) | 577 (38.57) | 161 (46.67) | 75 (47.47) | 5 (22.73) | 0.003 |
| Hypertension n (%) | 1265 (84.5) | 325 (93.93) | 150 (93.75) | 19 (86.36) | <0.001 |
| Hypercholesterolemia n (%) | 1182 (78.91) | 285 (82.37) | 126 (80.25) | 20 (90.91) | 0.27 |
| History of heart failure n (%) | 401 (26.75) | 125 (36.13) | 68 (42.5) | 12 (52.17) | <0.001 |
| Ejection fraction % mean (SD) | 52.4 (13.4) | 52.9 (12.6) | 47.6 (14.6) | 42.4 (13.8) | <0.001 |
| History of stroke n (%) | 106 (11.83) | 43 (12.5) | 29 (18.35) | 2 (9.09) | 0.14 |
| History of myocardial infarction n (%) | 405 (27.09) | 100 (29.07) | 88 (63.77) | 17 (80.95) | <0.001 |
| History of PCI n (%) | 741 (49.43) | 201 (58.09) | 93 (58.13) | 15 (65.22) | 0.004 |
| History of CABG n (%) | 440 (29.35) | 96 (27.75) | 48 (30) | 4 (17.39) | 0.58 |
| ACE/ARB use n (%) | 481 (52.45) | 208 (60.12) | 105 (65.63) | 15 (65.22) | 0.003 |
| Aspirin use n (%) | 1234 (82.38) | 303 (87.57) | 145 (90.63) | 21 (91.3) | 0.006 |
| Clopidogrel use n (%) | 561 (37.45) | 187 (54.05) | 104 (65) | 13 (56.52) | <0.001 |
| Statin use n (%) | 1150 (76.87) | 277 (80.06) | 130 (81.25) | 18 (78.26) | 0.41 |
| Beta blocker use n (%) | 1118 (74.63) | 285 (82.37) | 147 (91.88) | 21 (91.3) | <0.001 |
|
| |||||
| CD34+ cell/mL median (IQR) | 1624.97 (1032.96–2447.25) | 1574.93 (1039.89–2466.99) | 1887.68 (1248.71–2810.31) | 1890.62 (1178.71–3087.85) | 0.007 |
| CD34+/CD133+ cell/mL median (IQR) | 746.29 (445.71–1164.71) | 746.54 (467.53–1226.07) | 953.34 (579.09–1418.94) | 853.11 (304.2–1900.51) | 0.001 |
| CD34+/VEGF2R+ cell/mL median (IQR) | 20.02 (0–80.79) | 20.5 (7.58–71.87) | 29.82 (8.52–129.27) | 108.74 (8.46–260.07) | 0.001 |
| CD34+/CXCR4+ cell/mL median (IQR) | 760.68 (448.17–1246.08) | 722.4 (422.47–1258.69) | 963.48 (646.48–1666.94) | 914.52 (616.19–1377.87) | <0.001 |
*
P value for overall comparison between stable CAD vs. unstable angina vs. non-ST elevation myocardial infarction vs. ST-elevation myocardial infarction.